EMA Authorised: Mvasi (bevacizumab) — Amgen Technology (Ireland) UC

View source ↗

Summary

EMA authorised Mvasi (bevacizumab) from Amgen as a biosimilar to bevacizumab for multiple cancer indications including renal cell carcinoma, peritoneal cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Fallopian Tube Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Mvasi (Bevacizumab)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Renal Cell;Peritoneal Neoplasms;Ovarian Neoplasms;Breast Neoplasms;Carcinoma, Non-Small-Cell Lung;Fallopian Tube Neoplasms. MAH: Amgen Technology (Ireland) UC. Decision date: 19/12/2025